|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2005; 46:1411-1416, doi:10.1016/j.jacc.2005.04.064 © 2005 by the American College of Cardiology Foundation |
,*
* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
The TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Manuscript received January 27, 2005; revised manuscript received March 28, 2005, accepted April 4, 2005.
* Reprint requests and correspondence: Dr. Stephen D. Wiviott, TIMI Study Group, 350 Longwood Avenue, 1st Floor, Boston, Massachusetts 02115 (Email: swiviott{at}partners.org).
OBJECTIVES: This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy.
BACKGROUND: Intensive statin therapy reduces clinical events occurring after acute coronary syndrome (ACS) and may result in LDL levels markedly lower than guideline levels. Prior epidemiologic and preclinical studies raise concerns about the safety of very low cholesterol levels.
METHODS: The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) study compared intensive therapy (atorvastatin, 80 mg) and moderate therapy (pravastatin, 40 mg) in patients after ACS. Patients treated with atorvastatin were divided by four-month LDL values into groups: >100, >80 to 100 (reference-range-meeting guidelines), >60 to 80, >40 to 60, and <40 mg/dl. Baseline, clinical, and safety data were compared among groups achieving guideline recommendation levels or lower.
RESULTS: Among 1,825 patients with four-month LDL, 91% were at goal (<100 mg/dl). The distribution was >80 to 100 mg/dl (14%), >60 to 80 mg/dl (31%), >40 to 60 mg/dl (34%), and <40 mg/dl (11%). Those with lower LDL levels were more often male, older, and diabetic, and had lower baseline LDL levels. They had prior statin therapy and fewer prior myocardial infarctions (MI). There were no significant differences in safety parameters, including muscle, liver, or retinal abnormalities, intracranial hemorrhage, or death, in the very low LDL groups. The <40 mg/dl and 40 to 60 mg/dl groups had fewer major cardiac events (death, MI, stroke, recurrent ischemia, revascularization).
CONCLUSIONS: Compared with patients treated with an accepted LDL goal (80 to 100 mg/dl), there was no adverse effect on safety with lower achieved LDL levels, and apparent improved clinical efficacy. These data identify no intrinsic safety concern of achieving low LDL and, therefore, a strategy of intensive treatment need not be altered in patients achieving very low LDL levels.
| |||||||
This article has been cited by other articles:
|
|
 |
|
  M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo Review: Statins and stroke Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 R. W. Nesto LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach? Clin. Diabetes, January 1, 2008; 26(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tabas, K. J. Williams, and J. Boren Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications Circulation, October 16, 2007; 116(16): 1832 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Leeper, R. Ardehali, E. M. deGoma, and P. A. Heidenreich Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival Circulation, August 7, 2007; 116(6): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Afilalo, A. A Majdan, and M. J Eisenberg Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials Heart, August 1, 2007; 93(8): 914 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Qian, R. J. Schmidt, Y. Zhang, S. Chu, A. Lin, H. Wang, X. Wang, T. P. Beyer, W. R. Bensch, W. Li, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis J. Lipid Res., July 1, 2007; 48(7): 1488 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Davidson and J. G. Robinson Safety of Aggressive Lipid Management J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1753 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Patel, M. H. Shishehbor, and D. L. Bhatt A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis Eur. Heart J., March 2, 2007; 28(6): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Deedwania, P. H. Stone, C. N. Bairey Merz, J. Cosin-Aguilar, N. Koylan, D. Luo, P. Ouyang, R. Piotrowicz, K. Schenck-Gustafsson, P. Sellier, et al. Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE) Circulation, February 13, 2007; 115(6): 700 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S Houslay, J. Sarma, and N. G Uren The effect of intensive lipid lowering on coronary atheroma and clinical outcome Heart, February 1, 2007; 93(2): 149 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Drexel Reducing risk by raising HDL-cholesterol: the evidence Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F23 - F29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hulten, J. L. Jackson, K. Douglas, S. George, and T. C. Villines The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med, September 25, 2006; 166(17): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Keller and L. Lemberg Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association. Am. J. Crit. Care., September 1, 2006; 15(5): 514 - 518. [Full Text] [PDF]
|
|
|
|
 |
|
 The Stroke Prevention by Aggressive Reduction in C High-Dose Atorvastatin after Stroke or Transient Ischemic Attack N. Engl. J. Med., August 10, 2006; 355(6): 549 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF]
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas Highlights of the Year in JACC 2005 J. Am. Coll. Cardiol., January 3, 2006; 47(1): 184 - 202. [Full Text] [PDF]
|
|
|
|
 |
|
 Statins in ACS Patients: Intensity of Treatment, Timing of Benefit Journal Watch Cardiology, December 9, 2005; 2005(1209): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Can LDL Levels Be Too Low? Journal Watch Gastroenterology, November 29, 2005; 2005(1129): 4 - 4. [Full Text]
|
|
|
|
 |
|
 Can LDL Levels Be Too Low? Journal Watch (General), November 25, 2005; 2005(1125): 1 - 1. [Full Text]
|
|
|
|
 |
|
 C. P. Cannon The IDEAL Cholesterol: Lower Is Better JAMA, November 16, 2005; 294(19): 2492 - 2494. [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
